Skip to content
naulon
Not checkedNot checked for notices yet.

The intravenous use of commercial disinfectants in the treatment of Novel Coronavirus (COVID-19): Unconventional, but is there evidence against it?

Adarsh Shah, Edmund Leung

Asian Journal of Medical Sciences · 2020

doi:10.3126/ajms.v11i4.28941 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

Background: On 24th April 2020, United States President Donald J. Trump suggested the use of commercial surface disinfectants to treat patients infected with COVID-19. In his speech, President Trump also proposed medical research be conducted. However, there are controversies regarding the toxicity of the disinfectant’s main ingredients sodium hypochlorite. Aims and Objective: The purpose of this international collaborative study is to assess on feasibility and safety of disinfectants in human use. Materials and Methods: Several safety labels of common commercialised brands of surface disinfectant from United Kingdom and New Zealand. Furthermore, literature search was conducted through Pubmed on keywords keywords “sodium hypochlorite” AND “poisoning” AND “intravenous drug user”. Result: All safety labels advised hazardous warning regarding irritation and caustic burns if ingested. They all suggest water to wash out the effect if exposed to any mucus membrane such as eyes and broken skin. No safety information was given by any of the brands against subcutaneous or intravenous injection. No death in human was reported resulting from oral ingestion. There were 2 case reports: one of blindness and one of fibrosing alveolitis resulting from ingestion during a domestic dispute. Intravenous injection has only been seen in attempted murder cases or by intravenous drug users. All the reported cases have resulted in 2 deaths, organ failures and venous thrombosis including pulmonary embolism. Conclusion: There is no safety warning from the manufacturers of the studied surface disinfectants regarding intravenous use. Intravenous injections in the literature suggests significant toxic outcome including death. Randomised controlled trials on animals may be required to assess the risk of intravenous injection of surface disinfectants against the risk of death from COVID-19 infection.

Abstract licence: CC BY-NC

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.